Next Article in Journal
Assessment of Oral Poliovirus Vaccine Viability and Titer at Delivery Points in Kinshasa, the Democratic Republic of the Congo: Implications for Cold Chain Management
Previous Article in Journal
Rapid Progression of Cutaneous Lymphoma Following mRNA COVID-19 Vaccination: A Case Report and Pathogenetic Insights
Previous Article in Special Issue
Elimination of Human Papillomavirus 16-Positive Tumors by a Mucosal rAd5 Therapeutic Vaccination in a Pre-Clinical Murine Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 13
Issue 7
10.3390/vaccines13070679
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Brief Report

Disrupted Vaginal Microbiota and Increased HPV Infection Risk Among Non-Vaccinated Women: Findings from a Prospective Cohort Study in Kazakhstan

by
Kuralay Kongrtay
1,2,
Kuat Kassymbek
2,
Gulzhanat Aimagambetova
1,2,
Nazira Kamzayeva
2,*,
Sanimkul Makhambetova
2,
Makhabbat Galym
2,
Zhanar Abdiyeva
3,
Milan Terzic
1,2,
Kadisha Nurgaliyeva
3 and
Talshyn Ukybassova
2
1
Department of Surgery, School of Medicine, Nazarbayev University, Astana 010000, Kazakhstan
2
Clinical Academic Department of Women’s Health, CF “University Medical Center”, Astana 010000, Kazakhstan
3
Clinical Academic Department of Laboratory Medicine, Pathology and Genetics, CF “University Medical Center”, Astana 010000, Kazakhstan
*
Author to whom correspondence should be addressed.
Vaccines 2025, 13(7), 679; https://doi.org/10.3390/vaccines13070679 (registering DOI)
Submission received: 17 May 2025 / Revised: 12 June 2025 / Accepted: 16 June 2025 / Published: 25 June 2025
(This article belongs to the Special Issue Recent Research on Human Papillomavirus (HPV) Infection and Vaccination: 2nd Edition)
Browse Figure
Versions Notes

Abstract

Introduction: Vaginal microbiota has emerged as an important factor influencing human papillomavirus (HPV) persistence and host immunity. While HPV infection is often transient, persistent infections with high-risk HPV genotypes significantly increase the risk of cervical carcinogenesis. Thus, this study aims to investigate the association between microflora/sexually transmitted infections (STIs) and HPV infection, with a focus on the prevalence of coinfection and the potential role of genital tract microecological disorders. Methods: A prospective cohort study was conducted at a tertiary care center in Astana, Kazakhstan, between November 2024 and March 2025. A total of 396 non-pregnant women aged 18–45 years were enrolled during routine gynecological screening. Cervical samples were collected for high-risk HPV genotyping and the detection of 11 other vaginal microorganisms using real-time PCR. Results: HPV-positive women were significantly younger and more likely to be single compared to HPV-negative participants. They also had fewer pregnancies and deliveries and were more likely to use barrier contraception. Among STIs, Mycoplasma hominis demonstrated a significant association with HPV infection (adjusted OR = 2.16, 95% CI: 1.15–4.05, p = 0.017). Overall STI presence (adjusted OR = 2.16, p = 0.017) and STI multiplicity (adjusted OR = 1.36 per additional STI, p = 0.017) were also significantly associated with HPV positivity. Correlation analysis revealed a moderate association between Chlamydia trachomatis and Trichomonas vaginalis (ϕ = 0.39, p < 0.001), suggesting shared ecological or transmission pathways. Conclusion: The findings highlight the relevance of specific vaginal pathogens, particularly Mycoplasma hominis, and co-infection patterns in increasing the risk of HPV infection. These results underscore the importance of comprehensive STI screening and microbial profiling in cervical cancer prevention strategies, especially in populations with limited access to HPV vaccination. Further longitudinal and mechanistic studies are warranted to elucidate causal pathways and progression to cervical neoplasia.

1. Introduction

The human vagina is not sterile, and an actively self-sustaining ecosystem with a complex microenvironment plays a significant role in keeping the female genital tract healthy [1]. In reproductive-age women, the healthy vaginal microbiome is predominantly colonized by Lactobacillus species, such as L. crispatus, L. jensenii, and L. gasseri, which create an acidic and protective environment by contributing to epithelial barrier functioning, promoting immune homeostasis, and supporting spontaneous clearance of transient infections [2,3,4].
Various behavioral, hormonal, and physiological factors can disrupt this balance. This dysbiosis, marked by the overgrowth of anaerobic or aerobic organisms and the depletion of Lactobacillus, can lead to genital tract microecological disorders, increasing susceptibility to both endogenous and sexually transmitted infections [5,6]. Among these co-factors, sexually transmitted infections (STIs) have emerged as key contributors to the modulation of the cervical immune environment and viral persistence. Several epidemiological and molecular studies suggest that coinfection with common STIs, including Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Ureaplasma urealyticum, Ureaplasma parvum, and herpes simplex virus type 2 (HSV-2) can impair local immunity, increase inflammation, and facilitate the establishment or persistence of oncogenic HPV infections [7,8]. For example, C. trachomatis has been associated with increased susceptibility to HPV and may disrupt epithelial integrity, while the Mycoplasma and Ureaplasma species have shown subtype-specific associations with HPV persistence and immune evasion mechanisms [9,10].
In addition to specific pathogens, bacterial vaginosis (BV) and aerobic vaginitis (AV) have been increasingly recognized as important risk factors for HPV acquisition and persistence. These conditions are characterized by the depletion of protective Lactobacillus spp. and the overgrowth of potentially pathogenic anaerobes or aerobes, such as Gardnerella vaginalis, Prevotella spp., and Streptococcus agalactiae [11,12]. This imbalance leads to chronic inflammation, elevated levels of cytokines such as IL-1β and IL-6, and increased susceptibility to viral infections [5,13]. Moderate-to-severe AV, in particular, has been linked with a significantly higher prevalence of HPV infection, potentially acting as an independent cofactor in the pathogenesis of cervical neoplasia [14,15].
In Kazakhstan, cervical cancer continues to pose a major public health burden. As of 2022, the age-standardized incidence was 19 per 100,000 women, and cervical cancer ranked as the second cancer affecting women of reproductive age [16,17,18]. Following the World Health Organization (WHO) “90-70-90” Cervical Cancer Elimination Strategy, in 2024, Kazakhstan incorporated the HPV vaccination into the national vaccination calendar. The vaccination program follows a two-dose schedule, and the target group is 11-year-old girls. As a secondary prevention for cervical cancer, the national cervical cancer screening program employs the Papanicolaou test, which is implemented for women of 30–70 years old every 4 years. However, the screening coverage remains as low as 46%, not reaching the WHO target of 70% [17]. Nevertheless, despite the implementation of primary and secondary cervical cancer prevention strategies, limited STI surveillance, low public awareness, and inconsistent screening coverage challenge the effectiveness of existing prevention approaches [19]. Considering that HPV is a STI and could lead to potential synergistic effects between HPV and other STIs, understanding the pattern of co-infection is essential for optimizing cervical cancer prevention and the management of cervical precancerous lesions [20]. However, data from Central Asia on HPV-STI coinfections’ prevalence and clinical significance remain scarce and are published in Russian. Thus, this study aims to investigate the association between vaginal microflora/STIs and HPV infection, with a focus on the prevalence of coinfection and the potential role of genital tract microecological disorders.

2. Material and Methods

2.1. Study Design and Setting

A prospective cross-sectional cohort study was conducted in the Mother and Child Center, Corporate Fund University Medical Center (UMC), a tertiary care hospital in Astana, Kazakhstan. Samples were collected from November 2024 to March 2025. The study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [21].

2.2. Study Subjects

All women aged between 18 and 45 years old who met the eligibility criteria and signed the informed consent form were recruited to the study. The inclusion criteria comprise women aged 18–45 years old, who were not pregnant at the time of the study, and with a regular menstrual cycle. Exclusion criteria were the following: the presence of complex concomitant chronic diseases (hepatitis B and C, diabetes mellitus, autoimmune diseases, HIV-infected and oncological diseases at present and in history) in any location; acute inflammatory processes of any localization at the time of the study; use of probiotics and/or antibiotic therapy and/or immunosuppressive therapy within the previous 14 days; smoking; intrauterine device in situ; history of HPV vaccination; any invasive procedures and surgical interventions on organs, genitals within 45 days preceding the study.

2.3. Sample Collection and Study Settings

The samples were collected using an endocervical brush from the surface of the vaginal part of the cervix (exocervix) and the cervical canal (endocervix—the “transformation zone” of flat and columnar epithelium). These endocervical specimens were preserved in transport medium and sent to the laboratory on the same day.
The cervical smear samples were used to extract HPV DNA for further HPV genotyping, which was performed by utilizing RealBest kit (Vector Best, Koltsovo, Russian Federation) that identifies 12 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) according to the manufacturer’s instructions. The kit was validated in our previous studies [22,23]. The real-time PCR (RT-PCR) was performed with the CFX 96 RealTime PCR machine (Bio-Rad Laboratories, Hercules, CA, USA). Positive and negative controls were used for each PCR reaction. The positivity or negativity of the samples for HPV type were determined according to the manufacturer’s thresholds. The DNA concentration of the samples used was 3.75 ng/μL, resulting in 37.5 ng per well. The data produced were moved into the manufacturer’s software.
Detection of STIs (Mycoplasma genitalium, cytomegalovirus, HSV types 1 and 2, Trichomonas vaginalis, Ureaplasma urealyticum, Neisseria gonorrhoeae, Candida albicans, Chlamydia trachomatis, Gardnerella vaginalis, Mycoplasma chominis) was performed by the PCR quantitative method using a RealBest extraction 3 kit using the same machine—CFX 96 RealTime PCR, Bio-Rad Laboratories.

2.4. Study Variables

To define the factors that increase the risk of high-risk HPV, the next independent variables were examined: social and demographic features of participants (age, ethnicity, and residence); marital status (married, in a committed relationship; single) and past medical history (number of children, delivery, abortions, etc.); number of sexual partners, and data on gynecological health (menarche, age at the sexual debut, gynecological diseases, gynecological surgeries, history of sexually transmitted infections (STIs), etc.).

2.5. Statistical Analysis

The baseline characteristics of study participants were compared between groups stratified by HPV status and STI status. Based on the assessment of data distribution and assumptions for statistical tests, group comparisons were conducted using independent samples t-tests, Mann–Whitney U tests for continuous variables, and chi-square or Fischer’s exact tests for categorical variables. Additional intercomparisons were performed to evaluate the distribution of HPV and STI positivity and multiplicity across HPV and STI groups. To assess the associations between individual STIs and HPV status, univariate and multivariate binary logistic regression models were built. Multivariable models were adjusted for age and barrier contraception use, based on the examination of collinearity and correlations between variables which differed significantly across HPV groups and showed potential for confounding or collider bias.
Statistical analyses, as well as the visualization of results, were conducted using Python version: 3.11.12 (NumPy: 2.0.2, Pandas: 2.2.2, Statsmodels: 0.14.4, SciPy: 1.15.3, Scikit-learn: 1.6.1, Matplotlib: 3.10.0, Seaborn: 0.13.2).

2.6. Ethical Consideration

This study was conducted following the Declaration of Helsinki and its subsequent modifications and approved by the Local Bioethics Committee of “UMC” Corporate Fund (Minutes No. 2024/02-013 of 10 May 2024). Before sample collection, all participants provided written informed consent. The research team complies with all principles of scientific ethics and biomedical research ethics, and maintains high standards of intellectual integrity when implementing the program. After signing the informed consent form, the patient was included in the study. No personal information about the patients was made available to the investigators during or after the study.

3. Results

3.1. Study Subjects Description

A total of 396 women unvaccinated against HPV aged 18 to 45 years participated in this prospective cohort study. The median age of HPV-negative women was 34.96 years (interquartile range (IQR): 31.60–40.00), which was significantly higher than that of HPV-positive women (median 33.86 years, IQR: 27.92–37.48, p = 0.001). Marital status differed significantly between groups (p = 0.0078), with a higher proportion of single women in the HPV-positive group (30.9%) compared to the HPV-negative group (18.7%). Other socio-demographic variables, including education level, BMI, menarche age, menstrual cycle regularity, and mode of delivery, did not differ significantly by HPV status (Table 1). In terms of clinical data and obstetrics medical history, HPV-positive women reported fewer pregnancies (mean 1.51 vs. 2.38, p < 0.001) and deliveries (mean 1.2 vs. 1.74, p = 0.0002) compared to HPV-negative women. A significant difference was also found in abortion history (p = 0.001). The number of abortions was higher among HPV and STI-negative women than among HPV and STI-positive women (0.36 and 0.33 vs. 0.13 and 0.26, respectively). The use of barrier contraception was more frequent among HPV-positive women (41.0%) than HPV-negative women (29.2%; p = 0.0171) (Table 1).

3.2. STI Prevalence and Associations

Among STI agents, Mycoplasma hominis showed a significant association with HPV infection after adjustment for other STIs, age, and the use of barrier contraception (adjusted OR = 2.13, 95% CI: 1.12–4.06, p = 0.021). The presence of any STIs, as well as the multiplicity of STIs, was not associated with HPV status in univariate models. No statistically significant associations were found for other organisms such as Gardnerella vaginalis, Chlamydia trachomatis, Candida albicans, or Cytomegalovirus (Table 2).
Logistic regression analysis, in which each STI was included as an individual binary predictor for the presence of HPV infection, revealed that only Mycoplasma hominis possesses a statistically significant association with HPV status. Specifically, the likelihood of testing positive for HPV in the presence of Mycoplasma hominis infection was more than twofold higher, with the result reaching statistical significance (p = 0.021). Although Chlamydia trachomatis showed a high estimated risk, the finding lacked stability due to a limited number of observations. No other STIs exhibited a significant association with HPV infection.
Age has a slight protective effect (OR = 0.955) in HPV-positive patients, both in a crude model and while adjusted for STIs and barrier contraception.
According to Figure 1, Mycoplasma hominis infection possesses a weak, yet statistically significant correlation with both HPV status (ϕ = 0.12, p = 0.018) and HPV multiplicity (ρ = 0.13, p = 0.011).
Moreover, correlation analysis revealed moderate positive associations between Chlamydia trachomatis and Trichomonas vaginalis (ϕ = 0.39, p < 0.000), as well as weak but significant correlations between Candida albicans and Gardnerella vaginalis (ϕ = 0.15, p = 0.002), and between Mycoplasma hominis and Mycoplasma genitalium (ϕ = 0.15, p = 0.004). These findings indicate the non-random co-occurrence of vaginal pathogens.

4. Discussion

The vaginal microflora is a dynamic and self-regulating ecosystem with a significant role in maintaining the female genital tract health [2]. Disruption of the balance between physiologic microbiota allows pathogenic species to grow. In this regard, a special risk is brought by HPV, which has a potential for long-term persistence and thus, causes cervical premalignant lesions and cervical cancer [2,18].
This study found that infection with Mycoplasma hominis, the presence of at least one STI, and a greater number of concurrent STIs were all significantly linked to HPV positivity in this Central Asian population. These results are consistent with other studies that have proposed that co-infections may facilitate the persistence of HPV by contributing to mucosal inflammation, altering immune responses, or compromising the integrity of the epithelial barrier [24,25]. Previous studies have noted a link between Mycoplasma hominis and HPV infection, suggesting that metabolic by-products produced by Mycoplasma hominis may contribute to a pro-inflammatory milieu that supports viral persistence and potentially the development of cervical lesions [26]. The results of our study support this interpretation, especially given the strength of the association observed after adjusting for potential confounding variables. The observed positive association between STI multiplicity and HPV may reflect cumulative exposure to mucosal damage, immune activation, and increased transmission opportunities, especially in sexually active populations with inconsistent condom use [27,28,29]. Moreover, according to research data, condoms do not fully protect from HPV, thus even using barrier methods of contraception women can contract HPV infection, which is in line with our findings [30,31].
The socio-demographic data indicate that HPV positivity is more common among younger and single women, which is in line with patterns reported in international studies [19]. Differences in reproductive history—specifically, the lower number of pregnancies and deliveries among HPV-positive participants—may reflect a combination of behavioral and biological factors that influence both reproductive outcomes and susceptibility to infection. The correlation analysis also revealed the noteworthy co-occurrence of certain STIs, pointing to either overlapping modes of transmission or shared biological environments. In particular, the observed association between Chlamydia trachomatis and Trichomonas vaginalis—both of which often present without symptoms and are sexually transmitted—underscores the importance of comprehensive STI screening in individuals diagnosed with HPV.

Strengths and Limitations

One of the key strengths of this study is its prospective cohort design, which enabled structured data collection and the timely assessment of HPV and co-infection status. By comparing HPV-positive and HPV-negative participants, the study offers valuable insights into microbial patterns associated with infection risk. Importantly, the exclusion of vaccinated individuals allowed for an unconfounded analysis of natural HPV infection dynamics. The sample size was relatively large, and the broad range of pathogens tested provided a comprehensive picture of co-infection trends in a population where such data have historically been scarce.
Nonetheless, there are several limitations that should be considered. While significant associations were identified, the study design does not permit conclusions about causality, and longitudinal follow-up would be needed to assess outcomes such as persistence of infection or progression to cervical pathology. Furthermore, the use of PCR-based diagnostics, while sensitive, does not capture microbial load or shifts in community structure, which are increasingly recognized as relevant to disease risk. The study population, drawn from a single screening center, may limit the generalizability of findings to other settings or demographics. In addition, although some behavioral data were collected, variables such as sexual partner dynamics, detailed contraceptive use, and socioeconomic context were not extensively addressed and may represent potential sources of residual confounding.

5. Conclusions

This study’s findings indicate a clear link between HPV infection and disruptions in vaginal microflora, particularly with Mycoplasma hominis and the presence of other sexually transmitted infections. Women with HPV were more likely to have one or more STIs, suggesting that microbial imbalance may create a more permissive environment for HPV acquisition or persistence.
These results support the idea that addressing vaginal infections and overall microbial health may be an important, yet often overlooked, part of HPV prevention. Incorporating broader STI screening and treatment into cervical cancer screening programs could improve early detection and reduce long-term risk, especially in populations with limited access to HPV vaccination.
Although this study cannot establish causation, it highlights the need for longer-term research using more advanced microbiome tools to explore how these microbial factors influence the course of HPV infections. Such work could help shape more comprehensive care strategies for women’s reproductive health.

Author Contributions

Conceptualization, T.U., G.A. and M.T.; methodology, G.A., T.U., N.K. and K.K. (Kuralay Kongrtay); software, K.K. (Kuat Kassymbek); validation, N.K., K.N. and Z.A.; formal analysis, K.K. (Kuralay Kongrtay) and K.K. (Kuat Kassymbek); investigation, G.A., Z.A., M.G., S.M., N.K. and K.N.; resources, T.U.; data curation, G.A., M.T., M.G., S.M. and K.K. (Kuralay Kongrtay); writing—original draft preparation, K.K. (Kuralay Kongrtay), G.A. and K.K. (Kuat Kassymbek); writing—review and editing, K.K. (Kuralay Kongrtay), M.T. and G.A.; visualization, K.K. (Kuralay Kongrtay) and K.K. (Kuat Kassymbek); supervision, T.U.; project administration, T.U.; funding acquisition, T.U. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan (Grant No. BR24992853, Title: National program for study of HPV with development of integrated approach to the effective diagnosis and treatment of precancerous conditions). Prof. Talshyn Ukybassova is a PI of the research project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the Local Bioethics Committee of “UMC” Corporate Fund (Minutes No. 2024/02-013 of 10 May 2024).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data can be shared up on request.

Acknowledgments

The authors would like to acknowledge the Nazarbayev University School of Medicine for the supportive atmosphere that enabled completion of this study.

Conflicts of Interest

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

  1. Occhipinti, S.; Incognito, G.G.; Palumbo, M. The influence of the vaginal ecosystem on vaginitis, bacterial vaginosis, and sexually transmitted diseases: An epidemiological study and literature review. Arch. Gynecol. Obstet. 2025, 311, 347–353. [Google Scholar] [CrossRef] [PubMed]
  2. Alizhan, D.; Ukybassova, T.; Bapayeva, G.; Aimagambetova, G.; Kongrtay, K.; Kamzayeva, N.; Terzic, M. Cervicovaginal Microbiome: Physiology, Age-Related Changes, and Protective Role Against Human Papillomavirus Infection. J. Clin. Med. 2025, 14, 1521. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  3. Vitali, D.; Wessels, J.M.; Kaushic, C. Role of sex hormones and the vaginal microbiome in susceptibility and mucosal immunity to HIV-1 in the female genital tract. AIDS Res. Ther. 2017, 14, 39. [Google Scholar] [CrossRef] [PubMed]
  4. Incognito, G.G.; Ronsini, C.; Palmara, V.; Romeo, P.; Vizzielli, G.; Restaino, S.; La Verde, M.; De Tommasi, O.; Palumbo, M.; Cianci, S. The Interplay Between Cervicovaginal Microbiota Diversity, Lactobacillus Profiles and Human Papillomavirus in Cervical Cancer: A Systematic Review. Healthcare 2025, 13, 599. [Google Scholar] [CrossRef]
  5. Donders, G.G.G.; Bellen, G.; Grinceviciene, S.; Ruban, K.; Vieira-Baptista, P. Aerobic vaginitis: No longer a stranger. Res. Microbiol. 2017, 168, 845–858. [Google Scholar] [CrossRef]
  6. Usyk, M.; Zolnik, C.P.; Castle, P.E.; Porras, C.; Herrero, R.; Gradissimo, A.; Gonzalez, P.; Safaeian, M.; Schiffman, M.; Burk, R.D.; et al. Cervicovaginal microbiome and natural history of HPV in a longitudinal study. PLoS Pathog. 2020, 16, e1008376. [Google Scholar] [CrossRef]
  7. Paula Almeida Cunha, A.; Kassandra Pereira Belfort, I.; Pedro Belfort Mendes, F.; Rodrigues Bastos Dos Santos, G.; Henrique de Lima Costa, L.; de Matos Monteiro, P.; Lemos Gaspar, R.; Borges Ferreira, M.; de Sá Ferreira, A.; Cristina Moutinho Monteiro, S.; et al. Human papillomavirus and Its Association with Other Sexually Transmitted Coinfection among Sexually Active Women from the Northeast of Brazil. Interdiscip. Perspect. Infect. Dis. 2020, 2020, 8838317. [Google Scholar] [CrossRef]
  8. Valasoulis, G.; Pouliakis, A.; Michail, G.; Magaliou, I.; Parthenis, C.; Margari, N.; Kottaridi, C.; Spathis, A.; Leventakou, D.; Ieronimaki, A.I.; et al. Cervical HPV Infections, Sexually Transmitted Bacterial Pathogens and Cytology Findings–A Molecular Epidemiology Study. Pathogens 2023, 12, 1347. [Google Scholar] [CrossRef]
  9. Gargiulo Isacco, C.; Balzanelli, M.G.; Garzone, S.; Lorusso, M.; Inchingolo, F.; Nguyen, K.C.D.; Santacroce, L.; Mosca, A.; Del Prete, R. Alterations of Vaginal Microbiota and Chlamydia trachomatis as Crucial Co-Causative Factors in Cervical Cancer Genesis Procured by HPV. Microorganisms 2023, 11, 662. [Google Scholar] [CrossRef]
  10. Tamarelle, J.; Thiébaut, A.C.M.; de Barbeyrac, B.; Bébéar, C.; Ravel, J.; Delarocque-Astagneau, E. The vaginal microbiota and its association with human papillomavirus, Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium infections: A systematic review and meta-analysis. Clin. Microbiol. Infect. 2019, 25, 35–47. [Google Scholar] [CrossRef]
  11. Onderdonk, A.B.; Delaney, M.L.; Fichorova, R.N. The Human Microbiome during Bacterial Vaginosis. Clin. Microbiol. Rev. 2016, 29, 223–238. [Google Scholar] [CrossRef]
  12. Anahtar, M.N.; Gootenberg, D.B.; Mitchell, C.M.; Kwon, D.S. Cervicovaginal Microbiota and Reproductive Health: The Virtue of Simplicity. Cell Host Microbe 2018, 23, 159–168. [Google Scholar] [CrossRef]
  13. Lu, Y.; Wu, Q.; Wang, L.; Ji, L. Chlamydia trachomatis enhances HPV persistence through immune modulation. BMC Infect. Dis. 2024, 24, 229. [Google Scholar] [CrossRef] [PubMed]
  14. Latorre-Millán, M.; Tristancho-Baró, A.; Burillo, N.; Ariza, M.; Milagro, A.M.; Abad, P.; Baquedano, L.; Borque, A.; Rezusta, A. HPV-Associated Sexually Transmitted Infections in Cervical Cancer Screening: A Prospective Cohort Study. Viruses 2025, 17, 247. [Google Scholar] [CrossRef]
  15. Coorevits, L.; Traen, A.; Bingé, L.; Van Dorpe, J.; Praet, M.; Boelens, J.; Padalko, E. Identifying a consensus sample type to test for Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Trichomonas vaginalis and human papillomavirus. Clin. Microbiol. Infect. 2018, 24, 1328–1332. [Google Scholar] [CrossRef] [PubMed]
  16. Aimagambetova, G.; Azizan, A. Epidemiology of HPV Infection and HPV-Related Cancers in Kazakhstan: A Review. Asian Pac. J. Cancer Prev. 2018, 19, 1175–1180. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  17. Aimagambetova, G.; Chan, C.K.; Ukybassova, T.; Imankulova, B.; Balykov, A.; Kongrtay, K.; Azizan, A. Cervical cancer screening and prevention in Kazakhstan and Central Asia. J. Med. Screen 2021, 28, 48–50. [Google Scholar] [CrossRef] [PubMed]
  18. Imankulova, B.; Babi, A.; Issa, T.; Zhumakanova, Z.; Knaub, L.; Yerzhankyzy, A.; Aimagambetova, G. Prevalence of Precancerous Cervical Lesions among Nonvaccinated Kazakhstani Women: The National Tertiary Care Hospital Screening Data (2018). Healthcare 2023, 11, 235. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  19. World Health Organization (WHO). Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem. 2021. Available online: https://www.who.int/publications/i/item/9789240014107 (accessed on 2 April 2025).
  20. Wang, L.; Zhu, L.; Li, H.; Ma, N.; Huang, H.; Zhang, X.; Li, Y.; Fang, J. Association between asymptomatic sexually transmitted infections and high-risk human papillomavirus in cervical lesions. J. Int. Med. Res. 2019, 47, 5548–5559. [Google Scholar] [CrossRef]
  21. von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Gøtzsche, P.C.; Vandenbroucke, J.P.; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. BMJ 2007, 335, 806–808. [Google Scholar] [CrossRef]
  22. Aimagambetova, G.; Babi, A.; Issanov, A.; Akhanova, S.; Udalova, N.; Koktova, S.; Balykov, A.; Sattarkyzy, Z.; Abakasheva, Z.; Azizan, A.; et al. The Distribution and Prevalence of High-Risk HPV Genotypes Other than HPV-16 and HPV-18 among Women Attending Gynecologists’ Offices in Kazakhstan. Biology 2021, 10, 794. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  23. Babi, A.; Issa, T.; Issanov, A.; Akilzhanova, A.; Nurgaliyeva, K.; Abugalieva, Z.; Ukybassova, T.; Daribay, Z.; Khan, S.A.; Chan, C.K.; et al. Prevalence of high-risk human papillomavirus infection among Kazakhstani women attending gynecological outpatient clinics. Int. J. Infect. Dis. 2021, 109, 8–16. [Google Scholar] [CrossRef] [PubMed]
  24. Gillet, E.; Meys, J.F.; Verstraelen, H.; Bosire, C.; De Sutter, P.; Temmerman, M. Association between bacterial vaginosis and cervical intraepithelial neoplasia: Systematic review and meta-analysis. PLoS ONE 2011, 6, e45201. [Google Scholar] [CrossRef] [PubMed]
  25. Ye, H.; Song, T.; Zeng, X.; Li, L.; Hou, M.; Xi, M. Association between genital mycoplasmas infection and human papillomavirus infection, abnormal cervical cytopathology, and cervical cancer: A systematic review and meta-analysis. Arch. Gynecol. Obstet. 2018, 297, 1377–1387. [Google Scholar] [CrossRef]
  26. Torrone, E.A.; Morrison, C.S.; Chen, P.L.; Kwok, C.; Francis, S.C.; Hayes, R.J.; Looker, K.J.; McCormack, S.; McGrath, N.; van de Wijgert, J.H.; et al. Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: An individual participant data meta-analysis of 18 HIV prevention studies. PLoS Med. 2018, 15, e1002511. [Google Scholar] [CrossRef]
  27. Xie, L.; Li, Q.; Dong, X.; Kong, Q.; Duan, Y.; Chen, X.; Li, X.; Hong, M.; Liu, T. Investigation of the association between ten pathogens causing sexually transmitted diseases and high-risk human papilloma virus infection in Shanghai. Mol. Clin. Oncol. 2021, 15, 132. [Google Scholar] [CrossRef]
  28. A, D.; Bi, H.; Zhang, D.; Xiao, B. Association between human papillomavirus infection and common sexually transmitted infections, and the clinical significance of different Mycoplasma subtypes. Front. Cell. Infect. Microbiol. 2023, 13, 1145215. [Google Scholar] [CrossRef]
  29. Kazakh Scientific Center of Dermatology and Infectious Diseases. STI Control: Recommendations of Kazakhstani Experts. 2024. Available online: https://kncdiz.kz/en/news/item/8011/ (accessed on 9 June 2025).
  30. Chelimo, C.; Wouldes, T.A.; Cameron, L.D.; Elwood, J.M. Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer. J. Infect. 2013, 66, 207–217. [Google Scholar] [CrossRef] [PubMed]
  31. Chih, H.J.; Lee, A.H.; Colville, L.; Xu, D.; Binns, C.W. Condom and oral contraceptive use and risk of cervical intraepithelial neoplasia in Australian women. J. Gynecol. Oncol. 2014, 25, 183–187. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
Vaccines 13 00679 g001
Figure 1. Correlation heatmap of vaginal pathogens.
Figure 1. Correlation heatmap of vaginal pathogens.
Vaccines 13 00679 g001
Table 1. Socio-demographic and clinical characteristics.
Table 1. Socio-demographic and clinical characteristics.
StatisticsHPV NegativeHPV PositiveSTI NegativeSTI Positive
AgeMean ± SD35.25 ± 6.1833.17 ± 6.6035.50 ± 6.1934.24 ± 6.44
Median [Q1–Q3]34.96 [31.60–40.00]33.86 [27.92–37.48]35.66 [31.40–39.99]34.26 [30.20–38.64]
Min–Max19.93–45.8819.90–46.0319.98–45.8719.90–46.03
Shapiro–Wilk (p)0.00030.01970.07890.0001
Levene’s p0.3625 0.7327
Statistic (p)t = 3.13p = 0.0019t = 1.63p = 0.1038
EthnicityKazakh236 (91.8%)125 (89.9%)82 (93.2%)279 (90.6%)
Russian12 (4.7%)8 (5.8%)2 (2.3%)18 (5.8%)
Uzbek0 (0.0%)1 (0.7%)0 (0.0%)1 (0.3%)
Ukranian2 (0.8%)0 (0.0%)1 (1.1%)1 (0.3%)
Uighur1 (0.4%)0 (0.0%)0 (0.0%)1 (0.3%)
Korean1 (0.4%)0 (0.0%)1 (1.1%)0 (0.0%)
Armenian2 (0.8%)0 (0.0%)0 (0.0%)2 (0.6%)
Bashkir1 (0.4%)0 (0.0%)0 (0.0%)1 (0.3%)
Tatar1 (0.4%)2 (1.4%)0 (0.0%)3 (1.0%)
German1 (0.4%)1 (0.7%)0 (0.0%)2 (0.6%)
Georgian0 (0.0%)1 (0.7%)1 (1.1%)0 (0.0%)
Macedonian0 (0.0%)1 (0.7%)1 (1.1%)0 (0.0%)
Statistic (p)Chi-square: 11.09p = 0.4354Chi-square: 16.03p = 0.1400
EducationIncomplete secondary2 (0.8%)1 (0.7%)1 (1.1%)2 (0.6%)
Secondary professional42 (16.3%)17 (12.2%)13 (14.8%)46 (14.9%)
Bachelor178 (69.3%)98 (70.5%)61 (69.3%)215 (69.8%)
Masters 32 (12.5%)21 (15.1%)11 (12.5%)42 (13.6%)
PhD 3 (1.2%)2 (1.4%)2 (2.3%)3 (1.0%)
Statistic (p)Chi-square: 1.58p = 0.8130Chi-square: 1.2p = 0.8784
Marital statusSingle48 (18.7%)43 (30.9%)20 (22.7%)71 (23.1%)
Married184 (71.6%)77 (55.4%)60 (68.2%)201 (65.3%)
Divorced22 (8.6%)18 (12.9%)8 (9.1%)32 (10.4%)
Widow3 (1.2%)1 (0.7%)0 (0.0%)4 (1.3%)
Statistic (p)Chi-square: 11.39p = 0.0098Chi-square: 1.35p = 0.7175
BMIMean ± SD23.85 ± 4.6223.36 ± 4.5623.93 ± 4.2923.61 ± 4.69
Median [Q1–Q3]23.14 [20.57–26.35]22.31 [20.26–25.56]23.20 [20.89–26.45]22.86 [20.39–25.84]
Min–Max15.78–43.2614.88–42.8016.65–43.2614.88–42.80
Shapiro–Wilk (p)0.00000.00000.00000.0000
Levene’s p0.8936 0.3703
Statistic (p)t = 1.03p = 0.3037t = 0.58p = 0.5639
MenarcheMean ± SD13.41 ± 1.3713.25 ± 1.2213.15 ± 1.3713.41 ± 1.30
Median [Q1–Q3]13.00 [13.00–14.00]13.00 [13.00–14.00]13.00 [12.00–14.00]13.00 [13.00–14.00]
Min–Max10.00–18.0010.00–17.0010.00–17.0010.00–18.00
Shapiro–Wilk (p)0.00000.00000.00040.0000
Levene’s p0.0454 0.5541
Statistic (p)U = 18,825.00p = 0.3537t = −1.66p = 0.0973
Duration of menstrual cycle Mean ± SD30.37 ± 9.8829.01 ± 3.7330.01 ± 8.4129.86 ± 8.26
Median [Q1–Q3]28.00 [28.00–30.00]28.00 [28.00–30.00]28.00 [28.00–30.00]28.00 [28.00–30.00]
Min–Max21.00–100.0020.00–60.0023.00–90.0020.00–100.00
Shapiro–Wilk (p)0.00000.00000.00000.0000
Levene’s p0.0716 0.9024
Statistic (p)t = 1.57p = 0.1182t = 0.15p = 0.8778
Regularity of menstrual cycle Regular239 (93.0%)132 (95.0%)82 (93.2%)289 (93.8%)
Irregular18 (7.0%)7 (5.0%)6 (6.8%)19 (6.2%)
Statistic (p)Chi-square: 0.3p = 0.5809Chi-square: 0.0p = 1.0000
Pain during menstruation Painless255 (99.2%)138 (99.3%)87 (98.9%)306 (99.4%)
Painful2 (0.8%)1 (0.7%)1 (1.1%)2 (0.6%)
Statistic (p)Fisher: 0.92p = 1.0000Fisher: 0.57p = 0.5305
Volume of menses Light7 (2.7%)3 (2.2%)2 (2.3%)8 (2.6%)
Medium250 (97.3%)136 (97.8%)86 (97.7%)300 (97.4%)
Statistic (p)Fisher: 1.27p = 1.0000Fisher: 0.87p = 1.0000
Number of sexual partnersMean ± SD1.57 ± 1.792.18 ± 5.421.61 ± 1.571.83 ± 3.91
Median [Q1–Q3]1.00 [1.00–1.00]1.00 [1.00–2.00]1.00 [1.00–1.00]1.00 [1.00–1.00]
Min–Max0.00–20.000.00–60.000.00–9.000.00–60.00
Shapiro–Wilk (p)0.00000.00000.00000.0000
Levene’s p0.0919 0.6804
Statistic (p)t = −1.65p = 0.0991t = −0.51p = 0.6100
Number of pregnanciesMean ± SD2.38 ± 1.911.51 ± 1.602.19 ± 1.892.04 ± 1.84
Median [Q1–Q3]2.00 [1.00–4.00]1.00 [0.00–2.00]2.00 [1.00–3.00]2.00 [0.00–3.00]
Min–Max0.00–8.000.00–9.000.00–8.000.00–9.00
Shapiro–Wilk (p)0.00000.00000.00000.0000
Levene’s p0.0128 0.6853
Statistic (p)U = 22,720.00p = 0.0000t = 0.69p = 0.4909
Number of deliveriesMean ± SD1.74 ± 1.391.20 ± 1.261.62 ± 1.341.53 ± 1.38
Median [Q1–Q3]2.00 [0.00–3.00]1.00 [0.00–2.00]2.00 [0.75–2.00]1.00 [0.00–2.00]
Min–Max0.00–5.000.00–5.000.00–5.000.00–5.00
Shapiro–Wilk (p)0.00000.00000.00000.0000
Levene’s p0.0737 0.4127
Statistic (p)t = 3.81p = 0.0002t = 0.56p = 0.5776
Number of abortionsMean ± SD0.36 ± 0.740.13 ± 0.430.33 ± 0.740.26 ± 0.63
Median [Q1–Q3]0.00 [0.00–0.00]0.00 [0.00–0.00]0.00 [0.00–0.00]0.00 [0.00–0.00]
Min–Max0.00–4.000.00–3.000.00–4.000.00–3.00
Shapiro–Wilk (p)0.00000.00000.00000.0000
Levene’s p0.0009 0.4012
Statistic (p)U = 20,258.00p = 0.0011t = 0.84p = 0.4012
Number of miscarriagesMean ± SD0.25 ± 0.590.16 ± 0.490.18 ± 0.540.22 ± 0.56
Median [Q1–Q3]0.00 [0.00–0.00]0.00 [0.00–0.00]0.00 [0.00–0.00]0.00 [0.00–0.00]
Min–Max0.00–3.000.00–3.000.00–3.000.00–3.00
Shapiro–Wilk (p)0.00000.00000.00000.0000
Levene’s p0.1391 0.5317
Statistic (p)t = 1.48p = 0.1391t = −0.63p = 0.5317
Mode of delivery
(History of C-section)		Only spontaneous vaginal 230 (89.5%)126 (90.6%)77 (87.5%)279 (90.6%)
At least one C-section27 (10.5%)13 (9.4%)11 (12.5%)29 (9.4%)
Statistic (p)Chi-square: 0.04p = 0.8502Chi-square: 0.42p = 0.5181
Abortionsno198 (77.0%)125 (89.9%)70 (79.5%)253 (82.1%)
yes59 (23.0%)14 (10.1%)18 (20.5%)55 (17.9%)
Statistic (p)Chi-square: 9.12p = 0.0025Chi-square: 0.16p = 0.6904
Ectopic pregnancyno248 (96.5%)137 (98.6%)84 (95.5%)301 (97.7%)
yes9 (3.5%)2 (1.4%)4 (4.5%)7 (2.3%)
Statistic (p)Fisher: 0.4p = 0.3416Fisher: 0.49p = 0.2716
Barrier contraception no182 (70.8%)82 (59.0%)58 (65.9%)206 (66.9%)
yes75 (29.2%)57 (41.0%)30 (34.1%)102 (33.1%)
Statistic (p)Chi-square: 5.16p = 0.0232Chi-square: 0.0p = 0.9659
Hormonal contraception no249 (96.9%)136 (97.8%)84 (95.5%)301 (97.7%)
yes8 (3.1%)3 (2.2%)4 (4.5%)7 (2.3%)
Statistic (p)Fisher: 0.69p = 0.7536Fisher: 0.49p = 0.2716
Any contraception no174 (67.7%)79 (56.8%)54 (61.4%)199 (64.6%)
yes83 (32.3%)60 (43.2%)34 (38.6%)109 (35.4%)
Statistic (p)Chi-square: 4.16p = 0.0414Chi-square: 0.19p = 0.6647
Any gynecological diseases no177 (68.9%)93 (66.9%)56 (63.6%)214 (69.5%)
yes80 (31.1%)46 (33.1%)32 (36.4%)94 (30.5%)
Statistic (p)Chi-square: 0.08p = 0.7736Chi-square: 0.82p = 0.3637
Cervical erosionno136 (52.9%)82 (59.0%)53 (60.2%)165 (53.6%)
yes121 (47.1%)57 (41.0%)35 (39.8%)143 (46.4%)
Statistic (p)Chi-square: 1.11p = 0.2919Chi-square: 0.97p = 0.3244
STI statusSTI negative53 (20.6%)35 (25.2%)––
STI positive204 (79.4%)104 (74.8%)
Statistic (p)Chi-square: 0.84p = 0.3604
STI multiplicityMean ± SD1.27 ± 0.941.44 ± 1.19––
Median [Q1–Q3]1.00 [1.00–2.00]1.00 [0.50–2.00]
Min–Max0.00–4.000.00–5.00
Shapiro–Wilk (p)0.00000.0000
Levene’s p0.0011
Statistic (p)U = 16,784.50p = 0.2995
HPV statusHPV negative––53 (60.2%)204 (66.2%)
HPV positive35 (39.8%)104 (33.8%)
Statistic (p)Chi-square: 0.84p = 0.3604
HPV multiplicityMean ± SD––0.60 ± 0.880.54 ± 0.93
Median [Q1–Q3]0.00 [0.00–1.00]0.00 [0.00–1.00]
Min–Max0.00–4.000.00–6.00
Shapiro–Wilk (p)0.00000.0000
Levene’s p0.5684
Statistic (p)t = 0.57p = 0.5684
Table 2. Association between vaginal pathogens with HPV infection.
Table 2. Association between vaginal pathogens with HPV infection.
STI ColumnCases in HPV−
(n = 257)		Cases in HPV+
(n = 139)		Crude ORCrude OR 2.5%Crude OR 97.5%Crude OR p-ValueAdjusted ORAdjusted OR 2.5%Adjusted OR 97.5%Adjusted OR p-Value
Candida albicans23 (8.94%)16 (11.51%)1.3230.6742.5980.4151.1790.5772.4090.651
Chlamydia trachomatis1 (0.39%)4 (2.88%)7.5850.83968.5390.0718.4950.72399.7950.089
Gardnerella vaginalis180 (70.04%)90 (64.75%)0.7860.5071.2180.2810.6470.4021.0390.072
Mycoplasma hominis25 (9.73%)25 (17.99%)2.0351.1193.7010.0202.1321.1204.0570.021
Trichomonas vaginalis2 (0.78%)3 (2.16%)2.8130.46417.0360.2611.9440.22616.6970.545
Ureaplasma urealyticum36 (14.01%)21 (15.11%)1.0930.6101.9570.7661.0230.5491.9050.943
Herpes simplex virus 1/21 (0.39%)2 (1.44%)3.7370.33641.5850.2841.2710.08718.5360.861
Cytomegalovirus52 (20.23%)36 (25.90%)1.3780.8472.2410.1961.5090.9022.5230.117
Mycoplasma genitalium6 (2.33%)3 (2.16%)0.9230.2273.7480.9110.6220.1402.7570.532
STI status204 (79.4%)104 (74.8%)0.7720.4741.2570.299––––
STI multiplicity1.27 ± 0.941.44 ± 1.191.1700.9601.4270.120––––
Barrier contraception75 (29.18%)57 (41.01%)1.6871.0952.5980.0181.5280.9582.4360.075
Age35.25 ± 6.1833.17 ± 6.600.9500.9190.9820.0020.9550.9210.9900.013
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kongrtay, K.; Kassymbek, K.; Aimagambetova, G.; Kamzayeva, N.; Makhambetova, S.; Galym, M.; Abdiyeva, Z.; Terzic, M.; Nurgaliyeva, K.; Ukybassova, T. Disrupted Vaginal Microbiota and Increased HPV Infection Risk Among Non-Vaccinated Women: Findings from a Prospective Cohort Study in Kazakhstan. Vaccines 2025, 13, 679. https://doi.org/10.3390/vaccines13070679

AMA Style

Kongrtay K, Kassymbek K, Aimagambetova G, Kamzayeva N, Makhambetova S, Galym M, Abdiyeva Z, Terzic M, Nurgaliyeva K, Ukybassova T. Disrupted Vaginal Microbiota and Increased HPV Infection Risk Among Non-Vaccinated Women: Findings from a Prospective Cohort Study in Kazakhstan. Vaccines. 2025; 13(7):679. https://doi.org/10.3390/vaccines13070679

Chicago/Turabian Style

Kongrtay, Kuralay, Kuat Kassymbek, Gulzhanat Aimagambetova, Nazira Kamzayeva, Sanimkul Makhambetova, Makhabbat Galym, Zhanar Abdiyeva, Milan Terzic, Kadisha Nurgaliyeva, and Talshyn Ukybassova. 2025. "Disrupted Vaginal Microbiota and Increased HPV Infection Risk Among Non-Vaccinated Women: Findings from a Prospective Cohort Study in Kazakhstan" Vaccines 13, no. 7: 679. https://doi.org/10.3390/vaccines13070679

APA Style

Kongrtay, K., Kassymbek, K., Aimagambetova, G., Kamzayeva, N., Makhambetova, S., Galym, M., Abdiyeva, Z., Terzic, M., Nurgaliyeva, K., & Ukybassova, T. (2025). Disrupted Vaginal Microbiota and Increased HPV Infection Risk Among Non-Vaccinated Women: Findings from a Prospective Cohort Study in Kazakhstan. Vaccines, 13(7), 679. https://doi.org/10.3390/vaccines13070679

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop